PlainPharmaWatch

CMS Open Payments · Program Year 2024

Human Regenerative Technologies

Human Regenerative Technologies reported $118,750.00 across General Payments, Research, and Ownership to 60 physicians and teaching hospitals across 61 transactions.

$118.8K
All-tracks total
61
Transactions
60
Recipients
#1140
of 1,925 companies

Human Regenerative Technologies reported $118,750.00 across all CMS Open Payments tracks (General + Research + Ownership) to 60 physicians and teaching hospitals in Program Year 2024 - ranking #1140 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $64,750.00, averaging $2.0K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer human-regenerative-technologies Human Regenerative Technologies

$118.8K · #1140/1,925 · 0.0% industry · PY2024

  • TOT $118.8K
  • RANK #1140
  • SHARE 0.0%
  • TXN 61
  • RCP 60
  • CAT 1
  • GEN $64.8K
  • TOP1 34.3%
  • PY 2024

Nearest volume peer: Noctrix Health, Inc. ($118.6K)

Neptune Medical Inc.$119.4KBrainlab, Inc.$119.2KHuman Regenerative Technolog…$118.8KNoctrix Health, Inc.$118.6KForte Bio-Pharma LLC$118.4K
All-tracks payment totals near Human Regenerative Technologies (CMS Open Payments PY2024)

Human Regenerative Technologies sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Human Regenerative Technologies

In Program Year 2024, Human Regenerative Technologies reported $118,750.00 in payments to 60 physicians and teaching hospitals across 61 individual transactions, an average of $1.9K per transaction and $2.0K per recipient. That total places Human Regenerative Technologies at rank #1140 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 1-category general-payment breakdown below at $64.8K (100.0% of General Payments, 60 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 1 types of general payments, Human Regenerative Technologies's largest category was "Compensation for Services Other Than Consulting" at $64.8K - 100.0% of General Payments.

How Human Regenerative Technologies divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$64.8K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $64.8K 60

Recipient Concentration in General Payments

The five largest recipient relationships account for $64,750.00 (100.0%) of $64,750.00 in this company's General Payments records across 5 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Human Regenerative Technologies

The five named recipients with the highest reported General Payments from this company

Kay May Kwok$22.2KSteven Rosenberg$14.7KAlexandra Bujor$11.2KBen Naghi$10.7KFreya Marshall$6.0K
  1. 1

    Kay May Kwok

    $22,200.00 across 12 reported transactions

  2. 2

    Steven Rosenberg

    $14,650.00 across 12 reported transactions

  3. 3

    Alexandra Bujor

    $11,200.00 across 12 reported transactions

  4. 4

    Ben Naghi

    $10,700.00 across 12 reported transactions

  5. 5

    Freya Marshall

    $6,000.00 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Human Regenerative Technologies's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Human Regenerative Technologies.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Human Regenerative Technologies.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Human Regenerative Technologies's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.